TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 ...
MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today ...
Kiniksa Pharmaceuticals announces Phase 2/3 trial for KPL-387, targeting recurrent pericarditis, expected mid-2025. Data available in late 2026. Kiniksa Pharmaceuticals announced that it is set to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果